N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer
ConclusionTCHL was a tolerable regimen at a starting L dose of 750 mg PO daily when given concurrently with chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Congestive Heart Failure | Docetaxel | Heart | Heart Failure | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Taxotere